Insys Therapeutics Announces First Patient Enrolled in Phase II Trial …

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company. 

“We are pleased to have begun enrollment in this important trial to treat cocaine dependence, a disease afflicting people in every part of society,” said Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer of Insys Therapeutics. “If successful, we anticipate subsequent studies to fully explore the potential of our CBD product as a much needed treatment option for those seeking to overcome their addiction.” 

Dr. Jutras-Aswad, lead investigator for this trial, added, “This is

... read more at: